GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Cyclically Adjusted PB Ratio

Cardiff Oncology (Cardiff Oncology) Cyclically Adjusted PB Ratio : 0.13 (As of May. 01, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Cardiff Oncology's current share price is $4.23. Cardiff Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $31.39. Cardiff Oncology's Cyclically Adjusted PB Ratio for today is 0.13.

The historical rank and industry rank for Cardiff Oncology's Cyclically Adjusted PB Ratio or its related term are showing as below:

CRDF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.03   Med: 0.07   Max: 0.7
Current: 0.14

During the past years, Cardiff Oncology's highest Cyclically Adjusted PB Ratio was 0.70. The lowest was 0.03. And the median was 0.07.

CRDF's Cyclically Adjusted PB Ratio is ranked better than
85.71% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs CRDF: 0.14

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cardiff Oncology's adjusted book value per share data for the three months ended in Dec. 2023 was $1.561. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $31.39 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cardiff Oncology Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cardiff Oncology's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Cyclically Adjusted PB Ratio Chart

Cardiff Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.55 0.18 0.04 0.05

Cardiff Oncology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.05 0.04 0.04 0.05

Competitive Comparison of Cardiff Oncology's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cardiff Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Cyclically Adjusted PB Ratio falls into.



Cardiff Oncology Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cardiff Oncology's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.23/31.39
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Cardiff Oncology's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.561/129.4194*129.4194
=1.561

Current CPI (Dec. 2023) = 129.4194.

Cardiff Oncology Quarterly Data

Book Value per Share CPI Adj_Book
201403 67.620 99.695 87.782
201406 66.005 100.560 84.948
201409 47.056 100.428 60.640
201412 31.783 99.070 41.520
201503 69.796 99.621 90.673
201506 52.450 100.684 67.419
201509 132.889 100.392 171.313
201512 117.914 99.792 152.921
201603 99.502 100.470 128.172
201606 77.794 101.688 99.009
201609 62.999 101.861 80.043
201612 46.367 101.863 58.911
201703 24.831 102.862 31.242
201706 8.134 103.349 10.186
201709 7.454 104.136 9.264
201712 8.873 104.011 11.041
201803 5.726 105.290 7.038
201806 6.060 106.317 7.377
201809 3.654 106.507 4.440
201812 2.632 105.998 3.214
201903 2.140 107.251 2.582
201906 1.626 108.070 1.947
201909 1.034 108.329 1.235
201912 0.851 108.420 1.016
202003 0.558 108.902 0.663
202006 1.143 108.767 1.360
202009 1.275 109.815 1.503
202012 3.484 109.897 4.103
202103 3.324 111.754 3.849
202106 3.512 114.631 3.965
202109 3.376 115.734 3.775
202112 3.346 117.630 3.681
202203 3.004 121.301 3.205
202206 2.782 125.017 2.880
202209 2.612 125.227 2.699
202212 2.380 125.222 2.460
202303 2.160 127.348 2.195
202306 1.938 128.729 1.948
202309 1.742 129.860 1.736
202312 1.561 129.419 1.561

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cardiff Oncology  (NAS:CRDF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cardiff Oncology Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology (Cardiff Oncology) Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.
Executives
Gary W Pace director C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar officer: Chief Medical Officer C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander officer: Chief Scientific Officer C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White director 310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage director C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Tod Smeal officer: Chief Scientific Officer 11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner officer: Chief Medical Officer 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin director C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob director
Vicki Kelemen officer: Exec. VP and COO 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116